Gene Silencing in Cancer in Association with Promoter Hypermethylation
The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Abstract
This article reviews the mechanisms of gene silencing in cancer and clinical applications of this phenomenon. The silencing of genes, especially tumor-suppressor genes, is a key event in the development of cancer. The silencing can be effected by a disabling mutation or by a shutting down of the promoter region, the site at which transcription of the gene begins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Self-citationMethylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Self-citationTargeted mutation of the DNA methyltransferase gene results in embryonic lethality
Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984
Hypomethylation distinguishes genes of some human cancers from their normal counterparts
Feinberg, A. P., & Vogelstein, B. (1983) · Nature · doi:10.1038/301089a0 · Cited by 2,437
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,344
Cited by
Items 201–207 of 207
Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer
Narayan, S., Bader, G. D., & Reimand, J. (2016) · Genome Medicine · doi:10.1186/s13073-016-0311-2 · Cited by 54
“Different classes of driver modifications are recognized, including chromosomal copy number alterations [2], epigenetic modifications in DNA methylation [3] and chromatin state [4], and DNA mutations such as short insertions-deletions and single nucleotide variants (SNVs).”
BackgroundHistone modifications as a pathogenic mechanism of colorectal tumorigenesis
Gargalionis, A. N., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.002 · Cited by 53
Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma
Burgucu, D., Guney, K., Sahinturk, D., Ozbudak, I. H., Ozel, D., Ozbilim, G., & Yavuzer, U. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-481 · Cited by 52
“Inactivation of many tumour suppressor gene products such as p53, p16INK4a, E-cadherin and PTEN [23-27] or activation of proto-oncogenes such as Cyclin D, EGFR and p63 [28-30] have been found to be implicated in HNSCC occurrence.”
BackgroundAn integrative analysis of DNA methylation and RNA-Seq data for human heart, kidney and liver
Xie, L., Weichel, B., Ohm, J. E., & Zhang, K. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-s3-s4 · Cited by 38
“Aberrant DNA methylation is also a hallmark of most cancers and the changes begin in the earliest pre-malignant and hyperplastic lesions, and throughout tumor progression, and contributes significantly to the biology of cancer [33-36], but the role of epigenetic/epigenomic changes in other diseases remains an area of…”
BackgroundEffects of quetiapine on DNA methylation in neuroblastoma cells
Sugawara, H., Bundo, M., Asai, T., Sunaga, F., Ueda, J., Ishigooka, J., Kasai, K., Kato, T., & Iwamoto, K. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.08.010 · Cited by 32
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0717 · Cited by 28
Incorrect Analysis of MCAM Gene Promoter Methylation in Prostate Cancer
Kocemba, K. A., Dudzik, P., Ostrowska, B., & Laidler, P. (2016) · The Prostate · doi:10.1002/pros.23210 · Cited by 6
“are inconsistent with the dogma that promoter CpG island methylation induces gene silencing during cancer progression [2,3].”
Background
Metadata
- Authors
- Herman, J. G., & Baylin, S. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-20
- Volume
- 349
- Issue
- 21
- Pages
- 2042-2054
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2040257851
- Cited by
- 3,422
- References
- 130
- FWCI
- 46.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.